• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Focus areas
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Focus areas
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesFocus areasTry Devex Pro
    • News
    • Devex CheckUp

    Devex Checkup: The secrets of South Africa’s COVID-19 vaccine deals

    In this week's edition: details of South Africa's COVID-19 vaccine deals released, Ugandan activists want donors to review programs after anti-gay bill, and END Fund's new board chair brings local approach in efforts to end NTDs.

    By Andrew Green // 07 September 2023

    Related Stories

    Devex CheckUp: Who will pay to end the AIDS epidemic?
    Devex CheckUp: Who will pay to end the AIDS epidemic?
    Devex Newswire: Will G20 add up to success or failure for South Africa?
    Devex Newswire: Will G20 add up to success or failure for South Africa?
    Devex CheckUp: Ozempic generics — promises galore, pitfalls aplenty
    Devex CheckUp: Ozempic generics — promises galore, pitfalls aplenty
    Devex CheckUp: Trump admin proposes sweeping cuts to global health
    Devex CheckUp: Trump admin proposes sweeping cuts to global health

    The South African government did not get a fair deal on its COVID-19 vaccines and now everyone knows it.

    The details of the government’s contracts with drug companies were publicly released this week, and among the most outrageous findings was that manufacturers such as Johnson & Johnson charged South Africa more for vaccines than they did wealthier countries in Europe. Although J&J says their final price was $7.50 per dose, which is lower than what they charged the EU.

    At the same time, some manufacturers prevented the South African government from donating their doses to other countries without permission. Some of the contracts also included broad indemnification clauses that pushed the liability onto the government if any complications arose.

    This article is free to read - just register or sign in

    Access news, newsletters, events and more.

    Join usSign in
    • Democracy, Human Rights & Governance
    • Global Health
    • Trade & Policy
    • Funding
    • The END Fund
    • Health Justice Initiative
    • South Africa
    • Uganda
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Andrew Green

      Andrew Green@_andrew_green

      Andrew Green, a 2025 Alicia Patterson Fellow, works as a contributing reporter for Devex from Berlin.

    Search for articles

    Related Stories

    Devex CheckUpRelated Stories - Devex CheckUp: Who will pay to end the AIDS epidemic?

    Devex CheckUp: Who will pay to end the AIDS epidemic?

    Devex NewswireRelated Stories - Devex Newswire: Will G20 add up to success or failure for South Africa?

    Devex Newswire: Will G20 add up to success or failure for South Africa?

    Devex CheckUpRelated Stories - Devex CheckUp: Ozempic generics — promises galore, pitfalls aplenty

    Devex CheckUp: Ozempic generics — promises galore, pitfalls aplenty

    Devex CheckUpRelated Stories - Devex CheckUp: Trump admin proposes sweeping cuts to global health

    Devex CheckUp: Trump admin proposes sweeping cuts to global health

    Most Read

    • 1
      Building stronger primary care to tackle NCDs and mental health
    • 2
      Collaborating for greater impact — Rwanda’s fight against AMR
    • 3
      Meet the innovators closing persistent gaps in women's health
    • 4
      Investing in opportunity: How venture capital powers social impact
    • 5
      Opinion: AI-powered technologies can transform access to health care
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement